Determining the Status of Tertiary Lymphoid Structures in Invasive Pulmonary Adenocarcinoma Based on Chest CT Radiomic Features

Overview

Journal Insights Imaging

Publisher Springer

Date 2025 Jan 29

PMID 39881024

Authors

Ye Yu

Tianshu Yang

Pengfei Ma

Yan Zeng

Yongming Dai

Yicheng Fu

Aie Liu

Ying Zhang

Guanglei Zhuang

Yan Zhou

Huawei Wu

Affiliations

Soon will be listed here.

Abstract

Objectives: The aim of this study was to determine the status of tertiary lymphoid structures (TLSs) using radiomic features in patients with invasive pulmonary adenocarcinoma (IA).

Methods: In this retrospective study, patients with IA from November 2015 to March 2024 were recruited from two independent centers (center 1, training and internal test data set; center 2, external test data set). TLS was divided into two groups according to hematoxylin-eosin staining. Radiomic features were extracted, and support vector machine (SVM) were implemented to predict the status of TLSs. Receiver operating characteristic (ROC) curves were used to analyze diagnostic performance. Furthermore, visual assessments of the test set were also conducted by two thoracic radiologists and compared with the radiomics results.

Results: A total of 456 patients were included (training data set, n = 278; internal test data set, n = 115; external test data set, n = 63). The area under the curve (AUC) of the radiomics model on the validation set, the internal test set, and the external test set were 0.781 (95% confidence interval (CI): 0.659-0.905;), 0.804 (95% CI: 0.723-0.884;) and 0.747 (95% CI: 0.621-0.874;), respectively. In the visual assessments, the mean CT value and air bronchogram were important indicators of TLS, the AUC was 0.683. In the external test set, the AUC of the clinical model was 0.632.

Conclusions: The radiomics model has a higher AUC than the clinical model and effectively discriminates TLSs in patients with IA.

Critical Relevance Statement: This study demonstrates that the radiomics-based model can differentiate TLSs in patients with IA. As a non-invasive biomarker, it enhances our understanding of tumor prognosis and management.

Key Points: TLSs are closely related to favorable clinical outcomes in non-small cell lung cancer. Radiomics from Chest CT predicted TLSs in patients with IA. This study supports individualized clinical decision-making for patients with IA.

References

Chen L, Gu D, Chen Y, Shao Y, Cao X, Liu G . An artificial-intelligence lung imaging analysis system (ALIAS) for population-based nodule computing in CT scans. Comput Med Imaging Graph. 2021; 89:101899. DOI: 10.1016/j.compmedimag.2021.101899. View

van Dijk N, Gil-Jimenez A, Silina K, Hendricksen K, Smit L, de Feijter J . Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial. Nat Med. 2020; 26(12):1839-1844. DOI: 10.1038/s41591-020-1085-z. View

Dieu-Nosjean M, Goc J, Giraldo N, Sautes-Fridman C, Fridman W . Tertiary lymphoid structures in cancer and beyond. Trends Immunol. 2014; 35(11):571-80. DOI: 10.1016/j.it.2014.09.006. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Federico L, McGrail D, Bentebibel S, Haymaker C, Ravelli A, Forget M . Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small-cell lung cancer. Ann Oncol. 2021; 33(1):42-56. PMC: 10019222. DOI: 10.1016/j.annonc.2021.09.021. View

Zhang C, Wang X, Zuo J, Wang X, Feng X, Zhang B . Localization and density of tertiary lymphoid structures associate with molecular subtype and clinical outcome in colorectal cancer liver metastases. J Immunother Cancer. 2023; 11(2). PMC: 9923349. DOI: 10.1136/jitc-2022-006425. View

Meylan M, Petitprez F, Becht E, Bougouin A, Pupier G, Calvez A . Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer. Immunity. 2022; 55(3):527-541.e5. DOI: 10.1016/j.immuni.2022.02.001. View

Dieu-Nosjean M, Giraldo N, Kaplon H, Germain C, Fridman W, Sautes-Fridman C . Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers. Immunol Rev. 2016; 271(1):260-75. DOI: 10.1111/imr.12405. View

Schumacher T, Thommen D . Tertiary lymphoid structures in cancer. Science. 2022; 375(6576):eabf9419. DOI: 10.1126/science.abf9419. View

10.

Meylan M, Petitprez F, Lacroix L, Di Tommaso L, Roncalli M, Bougouin A . Early Hepatic Lesions Display Immature Tertiary Lymphoid Structures and Show Elevated Expression of Immune Inhibitory and Immunosuppressive Molecules. Clin Cancer Res. 2020; 26(16):4381-4389. DOI: 10.1158/1078-0432.CCR-19-2929. View

11.

Rodriguez A, Engelhard V . Insights into Tumor-Associated Tertiary Lymphoid Structures: Novel Targets for Antitumor Immunity and Cancer Immunotherapy. Cancer Immunol Res. 2020; 8(11):1338-1345. PMC: 7643396. DOI: 10.1158/2326-6066.CIR-20-0432. View

12.

Fridman W, Meylan M, Petitprez F, Sun C, Italiano A, Sautes-Fridman C . B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome. Nat Rev Clin Oncol. 2022; 19(7):441-457. DOI: 10.1038/s41571-022-00619-z. View

13.

Stowman A, Hickman A, Mauldin I, Mahmutovic A, Gru A, Slingluff Jr C . Lymphoid aggregates in desmoplastic melanoma have features of tertiary lymphoid structures. Melanoma Res. 2018; 28(3):237-245. PMC: 5912978. DOI: 10.1097/CMR.0000000000000439. View

14.

Dieu-Nosjean M, Antoine M, Danel C, Heudes D, Wislez M, Poulot V . Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol. 2008; 26(27):4410-7. DOI: 10.1200/JCO.2007.15.0284. View

15.

Xie M, Gao J, Ma X, Wu C, Zang X, Wang Y . Consolidation radiographic morphology can be an indicator of the pathological basis and prognosis of partially solid nodules. BMC Pulm Med. 2022; 22(1):369. PMC: 9520850. DOI: 10.1186/s12890-022-02165-x. View

16.

Ren F, Xie M, Gao J, Wu C, Xu Y, Zang X . Tertiary lymphoid structures in lung adenocarcinoma: characteristics and related factors. Cancer Med. 2022; 11(15):2969-2977. PMC: 9359870. DOI: 10.1002/cam4.4796. View

17.

Yu Y, Fu Y, Chen X, Zhang Y, Zhang F, Li X . Dual-layer spectral detector CT: predicting the invasiveness of pure ground-glass adenocarcinoma. Clin Radiol. 2022; 77(6):e458-e465. DOI: 10.1016/j.crad.2022.02.006. View

18.

Lambin P, Rios-Velazquez E, Leijenaar R, Carvalho S, van Stiphout R, Granton P . Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer. 2012; 48(4):441-6. PMC: 4533986. DOI: 10.1016/j.ejca.2011.11.036. View

19.

Ukita M, Hamanishi J, Yoshitomi H, Yamanoi K, Takamatsu S, Ueda A . CXCL13-producing CD4+ T cells accumulate in the early phase of tertiary lymphoid structures in ovarian cancer. JCI Insight. 2022; 7(12). PMC: 9309049. DOI: 10.1172/jci.insight.157215. View

20.

Overacre-Delgoffe A, Bumgarner H, Cillo A, Burr A, Tometich J, Bhattacharjee A . Microbiota-specific T follicular helper cells drive tertiary lymphoid structures and anti-tumor immunity against colorectal cancer. Immunity. 2021; 54(12):2812-2824.e4. PMC: 8865366. DOI: 10.1016/j.immuni.2021.11.003. View